Rheumatic Heart Disease Clinical Trial
Official title:
Randomised Controlled Trial Into the Role of Ramipril in Fibrosis Reduction in Rheumatic Heart Disease: The RamiRHeD Trial Protocol
Objective propose: to investigate the effect of Ramipril in suppressing ST2 (suppression of tumorigenicity 2) in the cardiac mitral valve in patients with Rheumatic Heart Disease. We hypothesized that we hypothesized that ramipril will improve rheumatic mitral valve fibrosis through the downregulation of ST2.
The efficacy of secondary prevention is limited in the prevention of RHD progression. For this reason, new strategies and therapies are needed to prevent the progression of RHD. Neutralizing inflammatory cytokines or antagonizing their receptor function has been considered as a useful therapeutic strategy to treat autoimmune diseases. In this respect, new therapies targeting ST 2 and their receptors as studied in some autoimmune diseases may promise a new approach for patients with RHD. Angiotensin II induces the upregulation of Transforming growth factor β (TGF-β) and latter the binding of IL-33 to sST2 and not to the natural ligand (ST2L). The binding of IL-33 to sST2 will cause fibrogenesis even more. Thus, ACEI is hypothesized to attenuate this vicious cycle through the inhibition of Angiotensin II and consequently increase Bradykinin that furtherly inhibits fibrosis through the negative regulation of angiotensin II activity in Mitogen Activator Protein Kinase (MAPK) pathways through the suppression of the Ca2+ response and the Na+ transportACE inhibitor were agents with anti-fibrosis effects. The investigators keen to investigate the effect of Ramipril in suppressing ST2 expression as biomarkers of fibrosis in cardiac mitral valve in patients with Rheumatic Heart Disease in the National Cardiac Center Harapan Kita hospital Jakarta Indonesia. This study was designed as a randomized clinical trial. Patients with mitral stenosis valvular dysfunction due to rheumatic process planned for cardiac valve replacement surgery were given Ramipril or placebo for a minimum of 12 weeks (3 months). ST2 expression will be analyzed as the fibrosis biomarker in the mitral valve. This study will be conducted in the Department of Cardiology and Vascular Medicine, University Indonesia, National Cardiac Center Harapan Kita Hospital, Jakarta, Indonesia from June 2019 ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05991219 -
Screening and Secondary Prevention Rheumatic Heart Disease Study
|
||
| Completed |
NCT02661763 -
Rheumatic Heart Disease Study in Lusaka
|
N/A | |
| Completed |
NCT02188862 -
Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region
|
N/A | |
| Completed |
NCT01178710 -
Effect of Simvastatin on Cardiac Function
|
N/A | |
| Recruiting |
NCT05693545 -
GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial
|
Phase 2 | |
| Completed |
NCT06150274 -
Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy
|
N/A | |
| Terminated |
NCT03926156 -
RIvoraxaban in Mitral Stenosis
|
Phase 3 | |
| Recruiting |
NCT05783375 -
Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda
|
N/A | |
| Completed |
NCT02474108 -
Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement
|
N/A | |
| Recruiting |
NCT04556188 -
The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
|
||
| Active, not recruiting |
NCT03346525 -
Determining the Impact of Penicillin in Latent RHD: The GOAL Trial
|
Phase 2 | |
| Recruiting |
NCT05504928 -
Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease
|
N/A | |
| Not yet recruiting |
NCT03549052 -
Right Ventricular Echo Assessment in Mitral Valve Replacement
|
||
| Recruiting |
NCT05487469 -
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
|
N/A | |
| Completed |
NCT05276999 -
Rheumatic Heart Disease Community Streptococcal Treatment Program "RESET"
|
N/A | |
| Completed |
NCT05668611 -
Train the Trainer Curriculum to Scale up AI Supported Echo for RHD Screening in a Public Health System
|
N/A | |
| Active, not recruiting |
NCT05211024 -
A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)
|
||
| Withdrawn |
NCT02832531 -
INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
|
Phase 3 | |
| Completed |
NCT01794884 -
Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery
|
Phase 2 | |
| Completed |
NCT00264524 -
DNA Typing of HLA-DR/DQ Alleles in Taiwan Chinese With Rheumatic Heart Disease
|
N/A |